Richard Bernstein Advisors LLC decreased its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 5.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 21,654 shares of the company's stock after selling 1,140 shares during the quarter. Richard Bernstein Advisors LLC's holdings in Cencora were worth $6,022,000 at the end of the most recent quarter.
Other large investors have also added to or reduced their stakes in the company. Hoey Investments Inc. bought a new position in shares of Cencora during the 1st quarter worth approximately $28,000. Banque Transatlantique SA bought a new position in shares of Cencora during the 4th quarter worth approximately $29,000. SBI Securities Co. Ltd. bought a new position in shares of Cencora during the 4th quarter worth approximately $30,000. Vermillion Wealth Management Inc. bought a new position in shares of Cencora during the 4th quarter worth approximately $38,000. Finally, OFI Invest Asset Management bought a new position in shares of Cencora during the 4th quarter worth approximately $41,000. Institutional investors own 97.52% of the company's stock.
Insiders Place Their Bets
In other news, Chairman Steven H. Collis sold 14,579 shares of Cencora stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $292.62, for a total transaction of $4,266,106.98. Following the completion of the sale, the chairman directly owned 311,913 shares of the company's stock, valued at approximately $91,271,982.06. The trade was a 4.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Robert P. Mauch sold 4,969 shares of Cencora stock in a transaction on Monday, April 21st. The stock was sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the sale, the chief executive officer directly owned 47,582 shares of the company's stock, valued at $13,766,900.06. This represents a 9.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 34,127 shares of company stock valued at $9,812,296 over the last 90 days. Company insiders own 10.80% of the company's stock.
Cencora Price Performance
Shares of COR traded up $6.20 during mid-day trading on Monday, reaching $302.43. 1,597,776 shares of the stock traded hands, compared to its average volume of 1,507,152. The firm has a fifty day moving average price of $291.12 and a 200 day moving average price of $267.80. The company has a market cap of $58.62 billion, a price-to-earnings ratio of 35.08, a price-to-earnings-growth ratio of 1.47 and a beta of 0.57. The company has a current ratio of 0.87, a quick ratio of 0.52 and a debt-to-equity ratio of 6.01. Cencora, Inc. has a 1 year low of $218.65 and a 1 year high of $309.35.
Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, beating analysts' consensus estimates of $4.07 by $0.35. The firm had revenue of $75.50 billion during the quarter, compared to analyst estimates of $75.41 billion. Cencora had a net margin of 0.55% and a return on equity of 344.71%. The business's revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the previous year, the business earned $3.80 EPS. As a group, equities research analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.
Cencora Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Friday, May 16th were given a dividend of $0.55 per share. The ex-dividend date was Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.73%. Cencora's dividend payout ratio (DPR) is currently 25.52%.
Analyst Ratings Changes
A number of equities research analysts recently commented on COR shares. Jefferies Financial Group lifted their price target on shares of Cencora from $275.00 to $300.00 and gave the stock a "hold" rating in a report on Monday, June 30th. UBS Group lifted their price target on shares of Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a report on Tuesday, April 29th. Bank of America lifted their price objective on shares of Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. Wall Street Zen upgraded shares of Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Finally, Citigroup lifted their price objective on shares of Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $306.33.
Get Our Latest Stock Analysis on COR
Cencora Profile
(
Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Featured Stories
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
